News

News Sep 4, 2026

The Week in Review in Prescription Drug Pricing: New P4AD Report, Rising Cancer Prices, and P4AD on MFN Deals

Yesterday, P4AD, in collaboration with We Are Más, and Brown University’s Information Futures Lab released The Price Patients Pay: How Unaffordable Prescription Drugs Shape the Health, Finances, and…

Read Article News Aug 28, 2026

The Week in Review in Prescription Drug Pricing: Bad Week for Pharma in Court, Potential Drugmaker Deals Coming Soon, and more

Big Pharma suffered two more courtroom defeats this week, delivering the 24th and 25th legal victories for Medicare negotiation and the patients who fought to make it law.

Read Article News Aug 21, 2026

The Week in Review in Prescription Drug Pricing: New Video: Your Voice Is Your Power, Drug Prices Fall as IRA Reforms Take Hold and more

In honor of National Patient Advocacy Day on Wednesday, P4AD released a new video, Your Voice Is Your Power, following patient advocates Kris Garcia, Sarah Wisniewski, and Amelia Schachter as they…

Read Article News Aug 14, 2026

The Week in Review in Prescription Drug Pricing: TrumpRx 6 Months In, P4AD Takes the Stage at Latino Health Summit, and more

Six months after the TrumpRx platform launched, we’re getting a clearer picture of who the program is helping — and its limitations.

Read Article News Aug 7, 2026

The Week in Review in Prescription Drug Pricing: Closed-Door Policy Change to Negotiation, $200 Billion in MFN Medicare savings, and more

An unnoticed CMS policy change delayed Medicare price negotiation for AbbVie’s blockbuster drug Creon for an additional seven years — despite Creon, a pancreatic enzyme replacement therapy…

Read Article News Jul 31, 2026

The Week in Review in Prescription Drug Pricing: Xeljanz to be Removed from Negotiations, End of Medicare Drug Premium Subsidies, and more

CMS announced that Xeljanz and Xeljanz XR will be removed from the Medicare Drug Price Negotiation Program in 2029 after determining the drugs will soon face generic competition.

Read Article News Jul 24, 2026

The Week in Review in Prescription Drug Pricing: Big Pharma Leads 2026 Health Lobbying, P4AD Warns Against Generic Tariffs Plan, and more

With two markups this week, the House E&C and Senate HELP Committees advanced three bipartisan, P4ADNow-supported drug pricing reforms.

Read Article News Jul 17, 2026

The Week in Review in Prescription Drug Pricing: Third FTC PBM Settlement, Patent Reform on Capitol Hill, and more

The Senate Judiciary Committee and the House Energy and Commerce Committee each held hearings this week on drug development and access, with lawmakers from both parties highlighting industry…

Read Article News Jul 10, 2026

The Week in Review in Prescription Drug Pricing: FDA Move on DTC Ads, HIV Drug Costs Surge for Medicare, CO PDAB Blocked, and more

The FDA is expected to strengthen transparency and warning requirements for direct-to-consumer (DTC) prescription drug advertisements as part of the administration’s 2026 regulatory agenda – a move…

Read Article News Jul 2, 2026

The Week in Review in Prescription Drug Pricing: BRIDGE, GLOBE & GUARD, and PBM lobbying ramps up

The administration’s GLP-1 “Bridge” program went into effect this week, offering eligible patients on Medicare access to weight loss drugs for $50 per month — marking the first time these treatments…

Read Article